In the hemophilia B study, 52 of the 54 subjects were able to achieve a mean factor IX activity above baseline of 36 IU/dL at 6 months and dropped minimally by 18 months to 34 IU/dL above baseline (25). The gene discussed is F9; the disease is hemophilia B.